-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HlrGTqv2A7ZAQ0RqrK+oSJkkii3+x1g0MAEENTTK9CeCi2Nxl9tZY1lrRsHLlnwH P8ogfR7RBEBRzc9j8/N2rQ== 0001047469-03-005568.txt : 20030214 0001047469-03-005568.hdr.sgml : 20030214 20030214141334 ACCESSION NUMBER: 0001047469-03-005568 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030211 ITEM INFORMATION: Other events FILED AS OF DATE: 20030214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSKARYOTIC THERAPIES INC CENTRAL INDEX KEY: 0000885259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043027191 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21481 FILM NUMBER: 03566090 BUSINESS ADDRESS: STREET 1: 195 ALBANY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6173490200 8-K 1 a2103556z8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 11, 2003 -------------------- TRANSKARYOTIC THERAPIES, INC. - -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in its Charter) Delaware - -------------------------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 000-21481 04-3027191 - -------------------------------------- --------------------------------------- (Commission File Number) (IRS Employer Identification No.) 700 Main Street, Cambridge, Massachusetts 02139 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (617) 349-0200 - -------------------------------------------------------------------------------- Registrant's Telephone Number, Including Area Code Not Applicable - -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) Item 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE. On February 11, 2003, the Board of Directors of Transkaryotic Therapies, Inc. ("TKT") appointed Michael J. Astrue as President and Chief Executive Officer and elected Mr. Astrue to serve as a member of the Board of Directors. Mr. Astrue, who previously served as TKT's Senior Vice President, Administration and General Counsel, assumed this new role effective immediately. Mr. Astrue replaced Dr. Richard F Selden, TKT's former President and Chief Executive Officer, whose resignation as President and Chief Executive Officer and as a director of TKT was accepted by the Board of Directors of TKT. David D. Pendergast, Ph.D., Senior Vice President, Technical Operations, was also promoted to Executive Vice President, Operations. In this newly created position, Dr. Pendergast will have line responsibility for a number of key departments including manufacturing, quality assurance, clinical development, and research. -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 14, 2003 REGISTRANT TRANSKARYOTIC THERAPIES, INC. By: /s/ Daniel E.Geffken ------------------------------- Daniel E. Geffken Senior Vice President, Finance and Chief Financial Officer -3- -----END PRIVACY-ENHANCED MESSAGE-----